- Home
- BPTH
as 02-05-2025 9:45am EST
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | BELLAIRE |
| Market Cap: | 4.8M | IPO Year: | N/A |
| Target Price: | $30.00 | AVG Volume (30 days): | 161.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.59 - $10.00 | Next Earning Date: | 03-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Bio-Path Holdings Inc. News
BPTH Breaking Stock News: Dive into BPTH Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Bio-Path Holdings Provides 2025 Clinical and Operational Update
MT Newswires
2 months ago
Sector Update: Health Care Stocks Mixed Premarket Thursday
MT Newswires
2 months ago
Sector Update: Health Care
MT Newswires
2 months ago
Bio-Path Says Preclinical Trials of BP1001-A Shows 'Enhanced Insulin Sensitivity' to Treat Obesity; Shares Surge Pre-Bell
GlobeNewswire
2 months ago
Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity
Newsfile
2 months ago
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 24
GlobeNewswire
2 months ago
Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients
GuruFocus.com
3 months ago
Bio-Path Holdings Inc (BPTH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial ...
Compare BPTH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BPTH Bio-Path Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.